Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)

NCT07287202 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Cortical Dysplasia
Tuberous Sclerosis Complex (TSC)
Hemimegalencephaly

Interventions

DRUG: SVG103

Sponsor

Sovargen